EP-202 / EpiThany, Aston Sci., University of Washington - LARVOL DELTA

Hanmi Pharmaceutical, ABL, Aptamer, 'Blood Cancer Treatment' Clinical Results Announced at American Society [Google translation] (Chosun Biz) - "Aptamer Science plans to present an abstract of its blood cancer treatment 'AST-202', which it is developing, at this year's conference....This presentation is expected to confirm the pharmacological characteristics of AST-202 and detailed animal experiment data. In the case of Paros I-Bio, the clinical phase 1 results will be presented as a poster this year as the research abstract for the acute myeloid leukemia treatment 'PHI-101' was adopted last year."

Clinical data • Preclinical • Acute Myelogenous Leukemia

Pharmacological and Pharmacokinetic Evaluation of AST-202, CD25-Targeted Aptamer Conjugated with Anti-Mitotic MMAE Warhead for the Treatment of Hematological Malignancies (ASH 2024) - "This improvement of stability was found to translate to improved PK profile relative to AST-202(1), resulting in the dramatic increase of AUC and half-life as well as the decreased CL.Cytotoxicity evaluation against a panel of human lymphoma and leukemia cell lines with different CD25-expression level revealed the correlation of the expression level of the target and CD25-negative Daudi and H929 cells (derived from B-cell lymphoma and multiple myeloma, respectively) were not affected in the range of treatment up to 1uM.Comparative in vivo study with subcutaneous xenografts of AST-202 and single MMAE-conjugated aptamer demonstrated CD25-specific tumor targeting and the superior anti-tumor efficacy of AST202 relative to ApDC with a single payload. The following study with a disseminated tumor model showed dramatic extensions of survival in all treatment groups compared with vehicle and non-binding ApDC controls and survival difference between AST-202(1) and AST-202(3) was..."

PK/PD data • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • IL2 • IL2RA

Aptamer Sciences Presents Anticancer Drug Research Results at ASH2024 [Google translation] (Medipana) - "Aptamer Sciences...announced on the 7th that it has secured research data demonstrating ApDC (aptamer-drug conjugate) technology targeting blood cancer...Aptamer Sciences conducted a comparative study of the drug with AST-202 and obtained significant results in tumor suppression effects. In a lymphoma model, it confirmed a tumor suppression effect superior to Adcetris, and in a survival rate evaluation, all AST-202 treatment groups achieved a survival rate of over 80%....In addition, AST-202 was confirmed to be relatively safe even when administered at a dose eight times higher than Adcetris, and was also confirmed to be superior in terms of toxicity."

Preclinical • Oncology • Solid Tumor

Infiltrative Peripheral T-Cell Lymphoma: A Rare Cause of Acute Liver Failure (ACG 2023) - "A case series by Rich et al. with 27 cases of ALF due to malignancy, initially found that 10 cases were indeterminant until liver biopsy showed malignancy, emphasizing the utility of obtaining a liver biopsy when the cause of ALF is uncertain."

CNS Disorders • Fatigue • Hematological Malignancies • Hepatology • Infectious Disease • Liver Failure • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

[VIRTUAL] EPO202 Cerebrovascular diseases 2 (EAN 2021) - No abstract available

CNS Disorders

[VIRTUAL] EPR202 Cognitive neurology/neuropsychology 1 (EAN 2021) - No abstract available